Clinical trial
Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and…
NCT00391638 · French National Agency for Research on AIDS and Viral Hepatitis, Other · Completed
Key facts
| NCT number | NCT00391638 |
|---|---|
| Title | Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients |
| Official title | Pilot Study on Efficacy and Tolerance of Peg-interferon Alpha-2a (Pegasys) Added to Tenofovir DF and Emtricitabine (Truvada) in AGHBe Positive HBV-HIV Co-infected Patients. ANRS HB 01 EMVIPEG. |
| Acronym | HB01EMVIPEG |
| Lead sponsor | French National Agency for Research on AIDS and Viral Hepatitis, Other |
| Collaborators | Gilead Sciences Industry Roche Pharma AG |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis B, HIV Infections |
| Intervention type | Biological, Drug |
| Interventions | TRUVADA (EMTRICITABINE + TENOFOVIR DF), PEGASYS 180μg (Interféron pégylé alpha -2a) |
| Enrollment | 56 |
| Start date | Jan 1, 2007 |
| Primary completion | May 1, 2011 |
| Completion | Oct 1, 2012 |
| First posted | Oct 24, 2006 |
| Last update posted | Jan 15, 2015 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: